Drugs. 2008;68(12):1691-8. doi: 10.2165/00003495-200868120-00006.


Cevimeline is an orally administered muscarinic receptor agonist that is indicated for the treatment of symptoms of dry mouth in patients with Sjogren's syndrome. Several well designed placebo-controlled trials demonstrated that 4-12 weeks' therapy with cevimeline 30 mg three times daily improved symptoms of dry mouth in patients with Sjogren's syndrome. Other symptoms, such as dry eye symptoms and overall dryness, also improved to a significantly greater extent with cevimeline than with placebo. Moreover, cevimeline significantly improved the salivary flow rate in patients with Sjogren's syndrome. Increased salivary flow was maintained in the longer term with cevimeline in patients with Sjogren's syndrome and symptoms of dry mouth, according to the results of an open-label 52-week study. From week 20 onwards, rates of patient and investigator satisfaction with the cevimeline dosage were > or =88%. Oral cevimeline 30 mg three times daily was generally well tolerated in patients with Sjogren's syndrome, with many of the most commonly reported adverse events reflecting the pharmacological action of the drug.

MeSH terms

  • Animals
  • Area Under Curve
  • Diarrhea / chemically induced
  • Female
  • Half-Life
  • Humans
  • Molecular Structure
  • Muscarinic Agonists / adverse effects
  • Muscarinic Agonists / pharmacokinetics*
  • Muscarinic Agonists / therapeutic use
  • Nausea / chemically induced
  • Quinuclidines / chemistry
  • Quinuclidines / pharmacokinetics*
  • Quinuclidines / therapeutic use
  • Randomized Controlled Trials as Topic
  • Rhinitis / chemically induced
  • Sjogren's Syndrome / drug therapy
  • Sjogren's Syndrome / metabolism
  • Sweating / drug effects
  • Thiophenes / chemistry
  • Thiophenes / pharmacokinetics*
  • Thiophenes / therapeutic use
  • Treatment Outcome


  • Muscarinic Agonists
  • Quinuclidines
  • Thiophenes
  • cevimeline